Dr. Farid Menaa is an inter-and multi-disciplinary Professor, Director, Entrepreneur and Consultant, he was awarded with a National Master in Genetics in 1999 and PhD in Medicine (Geriatry/Gerontology, Biochemistry and Biophysics) in 2003, both with highest distinctions from prestigious French universities. Dr. Menaa followed a post-doctoral in Oncology as a NIH-fellow (San Diego, California, USA; 2004–2007), during which he discovered a novel radiation-induced DNA Damage Signaling Pathway.Dr. Menaa was promoted as Chief Scientific Officer and Vice-President R&D at Fluorotronics, Inc. (CA, USA; 2009–1010), during which he actively participated in the development of Carbon-Fluorine Spectroscopy (CFS, aka Spectro-Fluor™) for bio-medical and pharmaceutical applications. Further, Dr. Menaa was appointed Principal Investigator in Hematology and Genomics as a FAPESP-Fellow (Sao Paulo, Brazil; 2010–2012) during which he discovered new genetic variants of stroke in sickle cell anemia patients. Dr. Menaa's main current focuses are related to preventive, personalized, translational, integrative and nanomedicine, especially in the areas of oncology, regenerative medicine and gerontology, in order to prevent and implement early diagnosis and efficient therapy.